Medical Oncology

RET+

Questions discussed in this category

Are you treating patients with RET-fusion+ metastatic NSCLC with RET inhibitors as the first line of therapy regardless of PD-L1 expression?

Are there scenarios in which you would proceed with checkpoint inhibitor for PDL1+ disease before having full molecular testing results?

5 Answers available

For patients with RET-fusion+ NSCLC who progress on RET inhibitors, do you repeat tumor molecular profiling before selecting subsequent therapy?

If yes, do you re-biopsy for tissue, or perform blood-based sequencing?

5 Answers available

Papers discussed in this category

JCO precision oncology, 2019

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-01

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Annals of oncology : official journal of the European Society for Medical Oncology, 2016-07

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

Clin Lung Cancer, 2020 Feb 10

Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.

JTO Clin Res Rep, 2020 May 13

Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC.

Ann Oncol, 2020 Sep 29

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.

Related Topics in Medical Oncology